Page 27 - 《中国药房》2024年23期

Chin J Gen Pract，2023，22（11）：1108-1117. Cooperative Group. Chinese consensus on diagnosis and
[ 2 ] 赵志刚，董占军，刘建平. 中国医疗机构药品评价与遴选 treatment of gastroesophageal reflux disease [J]. Chin J
快速指南：第二版[J]. 医药导报，2023，42（4）：447-456. Dig，2023，43（9）：588-598.
ZHAO Z G，DONG Z J，LIU J P. A quick guideline for [12] IWAKIRI K，FUJIWARA Y，MANABE N，et al.
drug evaluation and selection in Chinese medical institu‐ Evidence-based clinical practice guidelines for gastroeso-
tions：the second edition[J]. Her Med，2023，42（4）：447-456. phageal reflux disease 2021[J]. J Gastroenterol，2022，57
[ 3 ] ECHIZEN H. The first-in-class potassium-competitive （4）：267-285.
acid blocker，vonoprazan fumarate：pharmacokinetic and [13] XIAO Y L，ZHANG S T，DAI N，et al. Phase Ⅲ ，ran‐
pharmacodynamic considerations[J]. Clin Pharmacokinet， domised，double-blind，multicentre study to evaluate the
2016，55（4）：409-418. efficacy and safety of vonoprazan compared with lanso‐
[ 4 ] ZHOU L Y ，LU H，SONG Z Q ，et al.2022 Chinese na‐ prazole in Asian patients with erosive oesophagitis[J].
tional clinical practice guideline on Helicobacter pylori Gut，2020，69（2）：224-230.
eradication treatment[J]. Chin Med J （Engl），2022，135 [14] CHEN S F，LIU D L，CHEN H H，et al. The efficacy and
（24）：2899-2910. safety of keverprazan，a novel potassium-competitive acid
[ 5 ] SMITH S M，BOYLE B，BRENNAN D，et al. The second blocker，in treating erosive oesophagitis：a phase Ⅲ，ran‐
Irish Helicobacter pylori Working Group consensus for domised，double-blind multicentre study[J]. Aliment Phar‐
the diagnosis and treatment of Helicobacter pylori infec‐ macol Ther，2022，55（12）：1524-1533.
tion in adult patients in Ireland[J]. Eur J Gastroenterol [15] LEE K J，SON B K，KIM G H，et al. Randomised phase
Hepatol，2024，36（8）：1000-1009. Ⅲ trial：tegoprazan，a novel potassium-competitive acid
[ 6 ] Chinese Society of Gastroenterology，Cancer Collabora‐ blocker，vs. esomeprazole in patients with erosive oeso-
tion Group of Chinese Society of Gastroenterology，Chi‐ phagitis[J]. Aliment Pharmacol Ther，2019，49（7）：864-872.
nese Medical Association，et al. Guidelines for diagnosis [16] CASTELL D O，KAHRILAS P J，RICHTER J E，et al.
and treatment of chronic gastritis in China：2022，Shanghai Esomeprazole （40 mg） compared with lansoprazole （30
[J]. J Dig Dis，2023，24（3）：150-180. mg） in the treatment of erosive esophagitis[J]. Am J
[ 7 ] 中华消化杂志编辑委员会，邹多武，谢渭芬，等 . 消化性 Gastroenterol，2002，97（3）：575-583.
溃疡诊断与治疗共识意见：2022 年，上海[J]. 胃肠病学， [17] RAGHUNATH A S，GREEN J R B，EDWARDS S J. A re‐
2023，28（4）：208-225. view of the clinical and economic impact of using esome‐
Editorial Board of Chinese Journal of Digestion，ZOU prazole or lansoprazole for the treatment of erosive
D W，XIE W F，et al. Consensus on the diagnosis and esophagitis[J]. Clin Ther，2003，25（7）：2088-2101.
treatment of peptic ulcer：2022，Shanghai[J]. Chin J [18] HARUMA K，KINOSHITA Y，YAO T，et al. Randomised
Gastroenterol，2023，28（4）：208-225. clinical trial：3-year interim analysis results of the
[ 8 ] KAMADA T，SATOH K，ITOH T，et al. Evidence-based VISION trial to evaluate the long-term safety of vonopra‐
clinical practice guidelines for peptic ulcer disease 2020 zan as maintenance treatment in patients with erosive
[J]. J Gastroenterol，2021，56（4）：303-322. oesophagitis[J]. BMC Gastroenterol，2023，23（1）：139.
[ 9 ] MORAES-FILHO J P P，DOMINGUES G，CHINZON D， [19] GONG H Y，HAN D，LIU S，et al. Adverse events of
et al. Brazilian clinical guideline for the therapeutic ma- vonoprazan in the treatments of acid-related diseases：a
nagement of gastroesophageal reflux disease （Brazilian systematic review and meta-analysis[J]. Rev Esp Enferm
federation of gastroenterology，FBG）[J]. Arq Gastroen‐ Dig，2023，115（6）：294-300.
terol，2024，61：e23154. [20] TAN N D，MIAO X P，LIAO A J，et al. Efficacy and
[10] VALDOVINOS DÍAZ M A，AMIEVA-BALMORI M， safety of keverprazan compared with lansoprazole in the
CARMONA-SÁNCHEZ R，et al. Good clinical practice treatment of duodenal ulcer：a phase Ⅲ ，randomized，
recommendations for the diagnosis and treatment of double-blind，multicenter trial[J]. Clin Transl Gastroen‐
gastroesophageal reflux disease. An expert review from terol，2023，14（7）：e00602.
the Asociación Mexicana de Gastroenterología[J]. Rev [21] KIM J S，KO W，CHUNG J W，et al. Efficacy of
Gastroenterol Mex （Engl Ed），2024，89（1）：121-143. tegoprazan-based bismuth quadruple therapy compared
[11] 中华医学会消化病学分会胃肠动力学组，胃肠功能性疾 with bismuth quadruple therapy for Helicobacter pylori in‐
病协作组，食管疾病协作组. 中国胃食管反流病诊疗规 fection：a randomized，double-blind，active-controlled
范[J]. 中华消化杂志，2023，43（9）：588-598. study[J]. Helicobacter，2023，28（3）：e12977.
Gastroenterology Group of Gastrointestinal Motility of （收稿日期：2024-07-16 修回日期：2024-10-28）
the Chinese Medical Association，Gastrointestinal Func‐ （编辑：刘明伟）
tional Disease Cooperative Group，Esophageal Disease

中国药房 2024年第35卷第23期 China Pharmacy 2024 Vol. 35 No. 23 · 2857 ·